CMPX
Compass Therapeutics Inc.
NASDAQ: CMPX · HEALTHCARE · BIOTECHNOLOGY
$1.67
-9.24% today
Updated 2026-04-29
Market cap
$300.75M
P/E ratio
—
P/S ratio
269.28x
EPS (TTM)
$-0.42
Dividend yield
—
52W range
$2 – $7
Volume
6.7M
Compass Therapeutics Inc. (CMPX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $850000.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | -100.0% |
| Cost of revenue | $1.92M | $2.12M | $2.40M | $1.62M | $1.90M | $1.89M | — | — |
| Gross profit | $-1.92M | $-2.12M | $-2.40M | $-1.62M | $-1.90M | $-1.89M | $850000.00 | — |
| Gross margin | — | — | — | — | — | — | 100.0% | — |
| R&D | $27.09M | $22.45M | $14.90M | $20.34M | $30.00M | $38.12M | $42.34M | $55.97M |
| SG&A | $11.22M | $11.60M | $12.91M | $10.93M | $11.66M | $12.24M | $15.13M | $16.87M |
| Operating income | $-38.31M | $-34.05M | $-27.81M | $-81.88M | $-41.66M | $-50.36M | $-56.63M | $-72.84M |
| Operating margin | — | — | — | — | — | — | -6661.8% | — |
| EBITDA | $-35.73M | $-31.93M | $-25.41M | $-80.19M | $-39.75M | $-48.47M | $-54.87M | $-72.84M |
| EBITDA margin | — | — | — | — | — | — | -6455.5% | — |
| EBIT | $-37.65M | $-34.05M | $-27.81M | $-81.81M | $-41.66M | $-50.36M | $-56.63M | — |
| Interest expense | $767000.00 | $1.23M | $908000.00 | $370000.00 | $2.36M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-38.29M | $-34.74M | $-29.50M | $-82.18M | $-39.23M | $-42.49M | $-49.38M | $-66.49M |
| Net income growth (YoY) | — | +9.3% | +15.1% | -178.6% | +52.3% | -8.3% | -16.2% | -34.7% |
| Profit margin | — | — | — | — | — | — | -5808.8% | — |